ESC 2017
Does Oxygen Therapy Reduce Mortality in Suspected Acute MI?
Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air
Your search for supplemental oxygen returned 75 results
Drugs in the Pipeline
Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Drugs in the Pipeline, News
FDA Greenlights Study to Evaluate Opaganib in Patients With Moderate to Severe COVID-19
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Drugs in the Pipeline
NIH Trial Evaluating Remdesivir Plus Baricitinib for COVID-19 Initiated
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
News
NIH Trial Evaluating Hydroxychloroquine for COVID-19 Underway
Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.
Drugs in the Pipeline
NIH: Remdesivir Plus Interferon Beta-1a Being Evaluated for COVID-19
The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.
News
Efficacy of High-Flow O2 Tx Test Outside ICU for Infants With Bronchiolitis?
The researchers found that 12% of infants in the high-flow group received escalation of care due to treatment failure versus 23% in the standard-therapy group.
News
Oxygen Therapy for Mild COPD: Is It Beneficial?
Researchers find oxygen therapy does not improve quality of life, forestall hospitalization, lengthen lives
News
CDC: Cases of Vaping-Linked Lung Illness Now Top 1600
Related death toll has also risen to 34 fatalities, spread across 24 states
News
INOpulse Inhaled Nitric Oxide to Be Assessed for COVID-19 in Phase 3 Study
The Food and Drug Administration has cleared the initiation of a phase 3 trial evaluating INOpulse® inhaled nitric oxide (iNO) therapy (Bellerophon Therapeutics) in patients with coronavirus disease 2019 (COVID-19).
